A Study Comparing the Bioavailability of a Taste-masked Delafloxacin Powder for Oral Suspension With the Delafloxacin Tablet in Healthy Adults

A Phase 1, Single Part, Partially Randomised, Open-Label Study to Evaluate the Relative Bioavailability of a Taste-Masked Delafloxacin Powder for Oral Suspension With Oral Delafloxacin Tablet Reference in Healthy Subjects

This study will compare the bioavailability of a novel powder for oral suspension formulation of delafloxacin, intended for treatment of community acquired bacterial pneumonia, to that of the licensed delafloxacin oral tablet in healthy adults.

Key Inclusion Criteria:

• Must agree to adhere to the protocol-specified contraception requirements.
• Body mass index of 18.0 to 32.0 kilograms (kg)/meter squared as measured at screening.
• Weight ≥50 kg at screening.

Key Exclusion Criteria:

• Any history of hypersensitivity to delafloxacin or any other fluoroquinolones or previous history of tendon disorders related to fluoroquinolone administration.
• History of clinically significant cardiovascular, renal, hepatic, respiratory, or particularly gastrointestinal disease.
• Participant has a medical condition that may adversely affect taste or smell activity including but not limited to mouth ulcers, significant gum disease, and respiratory and/or sinus infection or cold.
• Clinically significant abnormal clinical chemistry, hematology or urinalysis as judged by the Investigator. Participants with Gilbert's Syndrome are not allowed.
• Participants who do not agree to eat a high-fat breakfast.

Note: Other inclusion/exclusion criteria may apply.